Intas Pharmaceuticals Ltd. has bought the assets and operations of Actavis Generics in the UK and Ireland for £603m, pipping a host of other suitors including some Indian peers. Intas will now figure in the top 20 generics players globally.
The assets on the block formed part of the Teva Pharmaceutical Industries Ltd./Allergan PLC divestiture, which is reported to have attracted interest from big pharma and private equity...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?